Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating activities:
Net loss	$ (429,138)	$ (314,410)	$ (363,012)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	12,462	11,007	10,989
Non-cash interest expense and amortization of debt issuance costs	9,162	12,897	22,526
Scilex Notes principal increase	28,000	0	0
Payment on Scilex Notes attributed to accreted interest related to the debt discount	(13,172)	0	0
Non-cash operating lease cost	3,855	3,702	4,053
Stock-based compensation	90,188	31,419	12,648
Acquired in-process research and development	24,208	42,992	75,301
Loss on debt extinguishment, net	6,695	51,939	27,810
Loss (gain) loss on derivative liability	300	(6,600)	36,792
Loss on marketable investments	15,013	0	0
Loss on equity method investments	126	5,844	3,909
Loss (gain) on contingent liabilities and acquisition consideration payable	9,198	0	(11,090)
Deferred income taxes	(35,927)	(2,125)	(373)
Changes in operating assets and liabilities, excluding effect of acquisitions:
Accounts receivable	(2,957)	(1,051)	10,622
Accrued payroll	(111)	4,945	5,678
Prepaid expenses and other current assets	(12,019)	6,445	(314)
Accounts payable	(3,878)	(3,677)	10,221
Accrued expenses and other liabilities	20,747	(1,188)	4,061
Deferred revenue	(1,024)	(362)	(945)
Other	(3,549)	(1,313)	(628)
Net cash used for operating activities	(281,821)	(159,536)	(172,996)
Investing activities:
Proceeds from sale of marketable investments	124,767	0	0
Purchases of property and equipment	(8,871)	(6,528)	(11,442)
Purchase of assets related to Semnur, net of cash acquired	0	0	(17,040)
Net cash used for investing activities	79,847	(39,923)	(38,173)
Financing activities:
Proceeds from exercises of stock options and warrants	15,420	98,351	8,851
Proceeds from short-term debt and working capital funding arrangements, net of issuance costs	49,743	18,587	8,000
Payments of debt and other obligations	(85,656)	(205,564)	(3,074)
Payments related to Semnur Share Exchange	0	(55,000)	0
Net cash provided by financing activities	181,332	174,239	78,885
Net change in cash, cash equivalents and restricted cash	(20,642)	(25,220)	(132,284)
Net effect of exchange rate changes on cash	843	915	(277)
Cash, cash equivalents and restricted cash at beginning of period	56,464	80,769	213,330
Cash, cash equivalents and restricted cash at end of period	36,665	56,464	80,769
Cash paid during the period for:
Income taxes	1,200	0	13
Interest	1,060	3,419	12,738
Supplemental disclosures of non-cash investing and financing activities:
Semnur acquisition costs incurred but not paid	0	0	601
Scilex Notes principal increase	28,000	0	0
ACEA acquisition consideration paid in equity	42,168	0	0
Right-of-use assets obtained in exchange for new and amended operating lease liabilities	49,459	1,878	6,777
Other acquisitions, license agreements and investments consideration paid in equity	13,689	9,544	0
Changes to noncontrolling interests from increased ownership in Scilex Holding	23,963	0	0
Conversion of convertible notes	0	0	53,983
Other loan forgiveness	7,304	0	0
Property and equipment costs incurred but not paid	1,253	600	849
Reconciliation of cash, cash equivalents and restricted cash within the Company's consolidated balance sheets:
Cash and cash equivalents	36,665	56,464	22,521
Restricted cash	0	0	58,248
Cash, cash equivalents, and restricted cash	36,665	56,464	80,769
Public Offering Of Common Stock And Warrants 2019
Operating activities:
Net loss		(314,410)
Financing activities:
Proceeds from issuance of common stock	201,825	317,865	47,697
SmartPharm
Supplemental disclosures of non-cash investing and financing activities:
Acquisition consideration paid in equity	0	19,421	0
Semnur
Supplemental disclosures of non-cash investing and financing activities:
Acquisition consideration paid in equity	0	0	54,591
ACEA Therapeutics, Inc
Changes in operating assets and liabilities, excluding effect of acquisitions:
Acquisition consideration payable	9,200
Investing activities:
Acquisition consideration paid in cash, net of cash acquired	(754)	0	0
Other Acquisitions and Investments
Investing activities:
Acquisition consideration paid in cash, net of cash acquired	35,295	33,395	9,691
Oaktree Term Loan
Financing activities:
Proceeds from Oaktree Term Loans, net of issuance costs	$ 0	$ 0	$ 17,411